Status: Pending
Age: New (13/08/2025)
Accumulate Zydus Lifesciences; target of ₹970: Prabhudas Lilladher
Brokerage
Prabhudas Lilladher
Analyst
Prabhudas Lilladher
Position
Neutral
Start Date
13/08/2025
Horizon
Mid Term
Target Price and Expected Returns
Start Price
1023.15
Target Price
₹970
Expected Returns
-5.2%
Summary
Prabhudas Lilladher recommended an accumulate rating on Zydus Lifesciences with a target price of ₹970 in its research report dated August 13, 2025.
Prabhudas Lilladher's justification for Zydus Lifesciences target price prediction
- Zydus Lifesciences Q1 EBITDA exceeded expectations by 5%.
- Revenue drivers including gRevlimid and gMirabegron contributed significantly to FY25/Q1FY26 EPS.
- The company has a strong pipeline of complex products like injectables, biosimilars, and vaccines, expected to materialize over the next 2-3 years.
- US sales projections show decline in FY27 due to product-specific sales erosion.
- Mgmt anticipates 2-3 significant launches in FY27/28 to sustain US sales momentum.
Sources:
https://www.moneycontrol.com/
Tags: